CIMA Labs Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CIMA Labs Inc.
Opioids Need Comparative Deterrence Studies, FDA Panel Says
Review of oral, nasal and intravenous abuse-deterrence claims for Teva's long-acting hydrocodone Vantrela ER highlights the lack of head-to-head studies against approved abuse-deterrent formulations and spurs debate on relevant comparators.
Teva's Opioid Vantrela: Conflicting Data On Oral Abuse Deterrence
Human abuse liking study, in vitro data paint different pictures of potential for hydrocodone extended-release product to deter oral abuse, FDA says ahead of advisory committee review; agency finds support for abuse-deterrent claims for intranasal, intravenous use.
Deals Shaping The Medical Industry, November 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Cephalon: Can Spec Pharma do R&D?
Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.